Accéder au contenu
Merck

[Role of rifaximin in correction of IBS-like symptoms in patients with inflammatory bowel disease].

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology (2013-12-04)
S S Belous, I L Khalif, O V Golovenko
RÉSUMÉ

One of the important problems in the treatment of patients with inflammatory bowel disease are the persistent complaints of pain, abdominal distention, frequent stools, excretion of mucus with faeces with the presence of endoscopic or roentgenologic remission in the damaged parts of gastrointestinal tract. In this review we describe possible causes of such complaints and some methods of their therapeutic correction.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Rifaximin
Rifaximin, European Pharmacopoeia (EP) Reference Standard
Rifaximin for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Rifaximin, VETRANAL®, analytical standard